Arrowhead Pharmaceuticals Inc (ARWR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) has a cash flow conversion efficiency ratio of 0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($20.49 Million) by net assets ($503.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Arrowhead Pharmaceuticals Inc (ARWR) total market value for the company's overall valuation and market capitalisation.
Arrowhead Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Arrowhead Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arrowhead Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arrowhead Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Arrowhead Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avantor Inc
NYSE:AVTR
|
0.032x |
|
Voya Financial Inc
NYSE:VOYA
|
-0.418x |
|
Shoprite Holdings Ltd
JSE:SHP
|
0.287x |
|
Autoliv Inc
ST:ALIV-SDB
|
-0.028x |
|
Affiliated Managers Group, Inc.
NYSE:AMG
|
0.072x |
|
Bluescope Steel Ltd
AU:BSL
|
0.086x |
|
Orkla ASA
OL:ORK
|
0.023x |
|
360 Security Technology Inc
SHG:601360
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Arrowhead Pharmaceuticals Inc (1997–2025)
The table below shows the annual cash flow conversion efficiency of Arrowhead Pharmaceuticals Inc from 1997 to 2025. View Arrowhead Pharmaceuticals Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $503.42 Million | $179.55 Million | 0.357x | +114.72% |
| 2024-09-30 | $191.06 Million | $-462.85 Million | -2.423x | -352.04% |
| 2023-09-30 | $287.16 Million | $-153.89 Million | -0.536x | -64.69% |
| 2022-09-30 | $418.34 Million | $-136.13 Million | -0.325x | -177.70% |
| 2021-09-30 | $408.82 Million | $171.22 Million | 0.419x | +302.75% |
| 2020-09-30 | $461.78 Million | $-95.39 Million | -0.207x | -129.13% |
| 2019-09-30 | $244.04 Million | $173.03 Million | 0.709x | +243.00% |
| 2018-09-30 | $95.24 Million | $-47.22 Million | -0.496x | -67.49% |
| 2017-09-30 | $80.87 Million | $-23.94 Million | -0.296x | +56.34% |
| 2016-09-30 | $95.02 Million | $-64.43 Million | -0.678x | -13.11% |
| 2015-09-30 | $109.62 Million | $-65.71 Million | -0.599x | -180.92% |
| 2014-09-30 | $165.99 Million | $-35.42 Million | -0.213x | +71.15% |
| 2013-09-30 | $25.73 Million | $-19.03 Million | -0.740x | +57.53% |
| 2012-09-30 | $8.81 Million | $-15.34 Million | -1.741x | -305.88% |
| 2011-09-30 | $12.56 Million | $-5.39 Million | -0.429x | +54.98% |
| 2010-09-30 | $8.08 Million | $-7.70 Million | -0.953x | +69.69% |
| 2009-09-30 | $4.86 Million | $-15.28 Million | -3.145x | -40.26% |
| 2008-09-30 | $12.30 Million | $-27.58 Million | -2.242x | -148.54% |
| 2007-09-30 | $26.46 Million | $-23.87 Million | -0.902x | -92.76% |
| 2006-09-30 | $31.61 Million | $-14.79 Million | -0.468x | -44.09% |
| 2005-09-30 | $28.02 Million | $-9.10 Million | -0.325x | -57.54% |
| 2004-09-30 | $11.23 Million | $-2.31 Million | -0.206x | -85.73% |
| 2003-09-30 | $1.42 Million | $-157.60K | -0.111x | -262.64% |
| 2002-09-30 | $-1.55 Million | $-105.83K | 0.068x | +8.82% |
| 2001-09-30 | $-1.30 Million | $-81.81K | 0.063x | -11.57% |
| 2000-09-30 | $-1.13 Million | $-80.09K | 0.071x | +100.61% |
| 1999-09-30 | $-996.10K | $-35.22K | 0.035x | +101.32% |
| 1998-09-30 | $-2.63 Million | $-46.15K | 0.018x | +1091.72% |
| 1997-09-30 | $-2.58 Million | $4.56K | -0.002x | -- |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more